KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Equity Average (2016 - 2025)

Historic Equity Average for Novavax (NVAX) over the last 15 years, with Q3 2025 value amounting to -$59.5 million.

  • Novavax's Equity Average rose 8757.52% to -$59.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$59.5 million, marking a year-over-year increase of 8757.52%. This contributed to the annual value of -$670.4 million for FY2024, which is 75.77% up from last year.
  • Latest data reveals that Novavax reported Equity Average of -$59.5 million as of Q3 2025, which was up 8757.52% from -$19.0 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Equity Average registered a high of $892.3 million during Q2 2021, and its lowest value of -$825.1 million during Q2 2023.
  • Its 5-year average for Equity Average is -$260.8 million, with a median of -$479.1 million in 2024.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 101157.48% in 2021, then plummeted by 119431.9% in 2022.
  • Novavax's Equity Average (Quarter) stood at $54.8 million in 2021, then plummeted by 1194.32% to -$600.0 million in 2022, then fell by 16.27% to -$697.6 million in 2023, then increased by 17.56% to -$575.1 million in 2024, then skyrocketed by 89.65% to -$59.5 million in 2025.
  • Its Equity Average was -$59.5 million in Q3 2025, compared to -$19.0 million in Q2 2025 and -$349.7 million in Q1 2025.